# Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

> **NCT02497781** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 97 (actual)

## Conditions studied

- Complicated Urinary Tract Infections

## Interventions

- **DRUG:** Ceftazidime -avibactam
- **DRUG:** Cefepime

## Key facts

- **NCT ID:** NCT02497781
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-24
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497781, "Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02497781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*